Several researchers have identified some molecular targets, such as the immune checkpoint programmed death-1 (PD-1) [31] and the tissue factor (TF) [32], associated with the development and chemo-resistance of cervical cancer; thus the targeted molecular therapy combined with chemotherapy provides new ideas for cervical cancer clinical therapy [33]. This evidence concerns the gene F3 and cervical carcinoma.